Additional Information

Description

Actemra (Tocilizumab) 20 mg/mL, 200 mg, is a prescription biologic medication available in a single-dose, preservative-free vial containing 10 mL of solution. It is a recombinant humanized monoclonal antibody that targets interleukin-6 (IL-6) receptors, inhibiting the inflammatory response. Actemra is primarily indicated for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, and cytokine release syndrome.

This formulation is designed for intravenous administration, ensuring controlled and effective delivery of the active ingredient. The preservative-free nature of the vial reduces the risk of potential adverse reactions associated with preservatives. Each vial contains 200 mg of tocilizumab in a 10 mL solution, providing a concentration of 20 mg/mL to accommodate weight-based dosing requirements.

Actemra functions by blocking IL-6-mediated signaling pathways, thereby reducing inflammation, joint damage, and systemic symptoms associated with autoimmune diseases. It has been shown to improve clinical outcomes in patients with moderate to severe rheumatoid arthritis who have had an inadequate response to conventional disease-modifying antirheumatic drugs (DMARDs).